To assess strut coverage in patients presenting an acute myocardial infarction and treated either with the SYNERGY stent or the Bioresorbable Vascular Scaffold, through a parallel group design.
Single center, simple-blind randomized controlled trial, comparing the SYNERGY stent with the BVS device through a parallel group design.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
22
Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty. Stent will be implanted according to manufacturer's and competent authority recommendations.
Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty. Stent will be implanted according to manufacturer's and competent authority recommendations.
Didier CARRIE
Toulouse, Toulouse, France
Number of uncovered stent struts at 3-months
To assess strut coverage
Time frame: at 3-months
Percentage of malposed uncovered struts
Assessed by optical coherence tomography
Time frame: at 3 months
Frequency of abnormal intrastent tissue
Assessed by optical coherence tomography
Time frame: at 3 months
Percentage of net volume obstruction
Assessed by optical coherence tomography
Time frame: at 3 months
Rates of in-stent late loss
Time frame: at 3 months
Rates of in-segment late loss
Time frame: at 3 months
Rates of binary restenosis
Time frame: at 3 months
Plasma CXCL10 protein as a potential of re-endothelialization
Time frame: at 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.